Blennow K - Search Results

1

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised.

Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R, Blennow K, Cummings J, van Duijn C, Nilsson PM, Dietrich PY, Scheltens P, Dubois B. Frisoni GB, et al. Among authors: blennow k. Nat Rev Neurosci. 2022 Jan;23(1):53-66. doi: 10.1038/s41583-021-00533-w. Epub 2021 Nov 23. Nat Rev Neurosci. 2022. PMID: 34815562 Free PMC article. Review.

2

Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid.

Prior R, Mönning U, Schreiter-Gasser U, Weidemann A, Blennow K, Gottfries CG, Masters CL, Beyreuther K. Prior R, et al. Among authors: blennow k. Neurosci Lett. 1991 Mar 11;124(1):69-73. doi: 10.1016/0304-3940(91)90824-d. Neurosci Lett. 1991. PMID: 1677459

3

The neurochemistry of Alzheimer's disease.

Blennow K, Cowburn RF. Blennow K, et al. Acta Neurol Scand Suppl. 1996;168:77-86. doi: 10.1111/j.1600-0404.1996.tb00378.x. Acta Neurol Scand Suppl. 1996. PMID: 8997425 Review.

4

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. Hesse C, et al. Among authors: blennow k. Neurosci Lett. 2001 Jan 19;297(3):187-90. doi: 10.1016/s0304-3940(00)01697-9. Neurosci Lett. 2001. PMID: 11137759 Clinical Trial.

5

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

Sjögren M, Davidsson P, Wallin A, Granérus AK, Grundström E, Askmark H, Vanmechelen E, Blennow K. Sjögren M, et al. Among authors: blennow k. Dement Geriatr Cogn Disord. 2002;13(2):112-8. doi: 10.1159/000048642. Dement Geriatr Cogn Disord. 2002. PMID: 11844893

6

Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.

Stefanova E, Blennow K, Almkvist O, Hellström-Lindahl E, Nordberg A. Stefanova E, et al. Among authors: blennow k. Neurosci Lett. 2003 Feb 27;338(2):159-63. doi: 10.1016/s0304-3940(02)01384-8. Neurosci Lett. 2003. PMID: 12566177 Clinical Trial.

7

Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.

Sáez-Valero J, Fodero LR, Sjögren M, Andreasen N, Amici S, Gallai V, Vanderstichele H, Vanmechelen E, Parnetti L, Blennow K, Small DH. Sáez-Valero J, et al. Among authors: blennow k. J Neurosci Res. 2003 May 15;72(4):520-6. doi: 10.1002/jnr.10599. J Neurosci Res. 2003. PMID: 12704813

8

CSF markers for incipient Alzheimer's disease.

Blennow K, Hampel H. Blennow K, et al. Lancet Neurol. 2003 Oct;2(10):605-13. doi: 10.1016/s1474-4422(03)00530-1. Lancet Neurol. 2003. PMID: 14505582 Review.

9

Cerebrospinal fluid markers for prediction of Alzheimer's disease.

Zetterberg H, Wahlund LO, Blennow K. Zetterberg H, et al. Among authors: blennow k. Neurosci Lett. 2003 Nov 27;352(1):67-9. doi: 10.1016/j.neulet.2003.08.011. Neurosci Lett. 2003. PMID: 14615052

10

Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease.

Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, Andreasen N, Lenhard B, Brookes AJ, Pedersen NL, Blennow K, Prince JA. Johansson A, et al. Among authors: blennow k. Hum Genet. 2004 May;114(6):581-7. doi: 10.1007/s00439-004-1107-9. Epub 2004 Mar 18. Hum Genet. 2004. PMID: 15034781

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,083 results

Search Page